Company news
Xortx Therapeutics, Inc. (TSXV:XRTX) news
Xortx Therapeutics, Inc. news releases on 6ix. Latest, Sep 18, 2026: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM)…
Press releases & updates
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market Opportunity
September 18, 2026
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO(TM)
September 10, 2026
XORTX Re-Engages Investor Relations Program
September 8, 2026
XORTX Announces Termination and Postponement of Investor Relations Program
August 28, 2026
XORTX Announces Director Resignation
July 31, 2026
XORTX Appoints New Director
July 29, 2026
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
May 18, 2026
XORTX Announces US$5 Million Public Offering
May 14, 2026
XORTX Meets Nasdaq Continued Listing Requirements
April 21, 2026
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
April 13, 2026
XORTX Confirms Effective Date of Share Consolidation
April 1, 2026
XORTX Announces Results of Annual and Special Meeting of Shareholders
March 26, 2026
XORTX Announces Change of Effective Date of Share Consolidation
March 26, 2026
XORTX Announces Share Consolidation
March 25, 2026
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
March 24, 2026
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
March 18, 2026
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation
March 13, 2026
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
March 5, 2026
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
February 4, 2026
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
December 31, 2025
XORTX Announces Closing of US$1.1 Million Registered Direct Offering
October 29, 2025
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
October 21, 2025
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
October 20, 2025
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
October 19, 2025
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
October 17, 2025
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
September 4, 2025
XORTX Initiates IND Preparation for XORLO™ in Gout Program
September 3, 2025
XORTX Initiates IND Preparation for XORLO(TM) in Gout Program
September 3, 2025
XORTX Completes USD $114,500 Private Placement
August 8, 2025
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
August 7, 2025
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
August 7, 2025
XORTX Announces USD $114,500 Private Placement
July 31, 2025
XORTX Completes Non-Brokered Private Placement of Units
July 22, 2025
XORTX Announces USD $925,000 Private Placement
June 26, 2025
XORTX Announces USD $3 Million Offering
May 19, 2025
XORTX Provides Update on FDA Type B Meeting Request
April 30, 2025
XORTX Announces Grant of European Patent
April 28, 2025
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 17, 2025
XORTX Announces Update for Discussion with the FDA
March 19, 2025
XORTX Commences Gout Program NDA Discussions with the FDA
February 24, 2025
Money Talk Radio with Ellis Martin: XORTX Therapeutics Inc. (NASDAQ:XRTX) Dr. Allen Davidoff-Look for More M&As in the Kidney Disease Remediation Space in the Future
April 21, 2024
MONEY TALK RADIO with XORTX Therapeutics Inc. (XRTX) Dr. Allen Davidoff Explains Advanced Drug Therapy for Kidney Disease and Diabetes
March 3, 2024
IIROC Trading Resumption - XRTX
November 5, 2021
IIROC Trading Halt - XRTX
November 4, 2021
CSE Bulletin: Consolidation - XORTX Therapeutics Inc. (XRX)
September 21, 2021
XORTX to Present at "Zoom With LD MICRO"
March 16, 2021
XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021
March 9, 2021